French cardiac monitoring startup Implicity reports 26% lower mortality as it raises €35 million

Implicity, an innovator in AI-driven cardiac remote monitoring out of Paris, has secured a €35 million funding round to accelerate its international expansion, particularly in the USA, while advancing its AI capabilities and developing next-generation heart failure prediction algorithms.

The round was led by European tech growth capital firm IRIS, alongside Five Arrows, the alternative assets arm of Rothschild & Co.

“I didn’t become a physician to manage data – I became one to treat patients,” says Dr. Arnaud Rosier, electrophysiologist, CEO and co-founder of Implicity. “This funding lets us care for patients at scale, catching the information through the noise to provide the best possible care – and that’s the future of cardiology I’ve been chasing since my first year as an electrophysiologist.”

Implicity’s financing is better understood when placed amid the flow of investment in European cardiac care, remote patient monitoring and AI-enabled MedTech in 2026.

EU-Startups has reported approximately €209.6 million across relevant or adjacent financings this year, including €6 million for Portugal’s remote patient monitoring company Hope Care, €16.6 million for UK-based AI respiratory diagnostics company TidalSense and €6 million for Swiss continuous-monitoring startup Xsensio.

France has been particularly active: Paris-based DentalMonitoring secured €84 million for its AI-powered remote orthodontic monitoring platform, Lifeaz raised €13 million for its connected defibrillator business, while Bordeaux and Tours-based FineHeart announced €83 million in private capital and EU grants for its advanced heart-failure technology.

Nicolas Herschtel, Partner at IRIS’ Growth team, added, “In the evolving HealthTech landscape, long-term success requires a rare combination of robust technology, strict regulatory clearance, and undeniable clinical utility. Implicity has proven to be a highly trusted partner to complex health systems because its platform directly addresses the administrative and operational crisis facing hospital workforces today.

“We are thrilled to back the team as they cement their leadership in the US market and drive the next phase of digital healthcare infrastructure.”

Founded in 2016, Implicity is a digital MedTech company specialising in cardiac remote monitoring and the development of software as a medical device to improve productivity and prediction. The company’s independent, universal platform monitors patients with cardiac implantable electronic devices (CIEDs) and heart failure.

According to the company, remote patient monitoring is the standard of care when it comes to cardiology. Today, care teams manage more data than ever, from cardiac implantable electronic devices to heart failure monitoring. While each new data stream provides valuable clinical insight, it also adds complexity for the clinicians piecing the full picture together.

Too much time is spent navigating multiple systems and triaging alerts to identify events that require action. This administrative burden reduces time available for direct patient care, potentially delaying responses to the events that matter most. Implicity says they solve this by providing a universal, AI-driven platform that aggregates, normalises, and analyses data across the full continuum of care – spanning cardiac rhythm management, heart failure, and beyond – regardless of device manufacturer.

The company’s technology has reportedly demonstrated a 26% reduction in mortality and a 4% reduction in hospitalisation.

That evidence has translated into adoption on both sides of the Atlantic where their platform is used daily at over 250 medical centers representing 120,000+ monitored patients. In France, Implicity runs across major public hospital networks, from AP-HP to CHU Tours or CHU Grenoble, and at Institut Mutualiste Montsouris it supported a move from 250 to 5,000 patients monitored, a twentyfold gain in the productivity of the monitoring team.

François-Xavier Lehman, Director at Five Arrows, says, “Implicity is a rare company where clinical superiority, regulatory credibility and genuine patient impact come together at scale. By turning fragmented cardiac data into action, it improves outcomes for patients while relieving the operational pressure on hospital teams. This is precisely the kind of sustainable, mission-driven business we seek to support.”

Today’s investment will accelerate Implicity’s international expansion, with a primary focus on scaling its commercial footprint and operations in the United States where the company has been operating from Cambridge (MA) since 2022. It will also fund the continued development of its AI capabilities by working on the next generation of Heart Failure prediction algorithms to better serve medical teams and optimise care for remotely monitored cardiac patients.

Implicity intends to become the platform that consolidates a “fragmented remote monitoring market“. Its technology is proving itself in cardiology, and that foundation is designed to extend into complementary new verticals.